PTGX Insider Trading

Insider Ownership Percentage: 5.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $16,620,133.94

Protagonist Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Protagonist Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$3.37MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Protagonist Therapeutics Share Price & Price History

Current Price: $52.40
Price Change: Price Decrease of -0.615 (-1.16%)
As of 03/18/2025 11:08 AM ET

This chart shows the closing price history over time for PTGX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$53.01Closing price on 03/17/25:

SEC Filings (Institutional Ownership Changes) for Protagonist Therapeutics (NASDAQ:PTGX)

98.63% of Protagonist Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PTGX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$343Mbought$71MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200M$0$200MTotal InflowsTotal Outflows
Protagonist Therapeutics logo
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More on Protagonist Therapeutics

Today's Range

Now: $52.40
Low: $51.84
High: $52.58

50 Day Range

MA: $39.93
Low: $35.09
High: $59.76

52 Week Range

Now: $52.40
Low: $24.22
High: $60.60

Volume

33,013 shs

Average Volume

736,726 shs

Market Capitalization

$3.22 billion

P/E Ratio

19.70

Dividend Yield

N/A

Beta

2.34

Who are the company insiders with the largest holdings of Protagonist Therapeutics?

Protagonist Therapeutics' top insider investors include:
  1. Dinesh V Ph D Patel (CEO)
  2. Suneel Gupta (Insider)
  3. Arturo Md Molina (Insider)
  4. Asif Ali (CFO)
  5. William D Waddill (Director)
Learn More about top insider investors at Protagonist Therapeutics.

Who are the major institutional investors of Protagonist Therapeutics?

Protagonist Therapeutics' top institutional shareholders include:
  1. Farallon Capital Management LLC — 9.95%
  2. RTW Investments LP — 9.23%
  3. Vanguard Group Inc. — 7.08%
  4. BVF Inc. IL — 3.19%
  5. Pacer Advisors Inc. — 3.15%
  6. Jefferies Financial Group Inc. — 2.50%
Learn More about top institutional investors of Protagonist Therapeutics stock.

Which major investors are selling Protagonist Therapeutics stock?

Within the previous quarter, PTGX stock was sold by these institutional investors:
  1. Jefferies Financial Group Inc.
  2. Marshall Wace LLP
  3. Driehaus Capital Management LLC
  4. Algert Global LLC
  5. Allspring Global Investments Holdings LLC
  6. Nuveen Asset Management LLC
  7. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
  8. Moody Aldrich Partners LLC
During the previous year, company insiders that have sold Protagonist Therapeutics company stock include:
  1. Dinesh V Ph D Patel (CEO)
  2. Suneel Gupta (Insider)
  3. Arturo Md Molina (Insider)
  4. Asif Ali (CFO)
  5. William D Waddill (Director)
Learn More investors selling Protagonist Therapeutics stock.

Which major investors are buying Protagonist Therapeutics stock?

Within the last quarter, PTGX stock was bought by institutional investors including:
  1. Deep Track Capital LP
  2. Wellington Management Group LLP
  3. American Century Companies Inc.
  4. Toronto Dominion Bank
  5. Toronto Dominion Bank
  6. Raymond James Financial Inc.
  7. Pictet Asset Management Holding SA
  8. Soleus Capital Management L.P.